How big is SIGA Technologies, Inc.?

As of Jun 18, SIGA Technologies, Inc. has a market capitalization of 450.08 million, with net sales of 120.33 million and a net profit of 48.52 million over the latest four quarters.

Market Cap: As of Jun 18, SIGA Technologies, Inc. has a market capitalization of 450.08 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, SIGA Technologies, Inc. reported net sales of 120.33 million and a net profit of 48.52 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 215.80 million and total assets of 244.84 million.

What does SIGA Technologies, Inc. do?

SIGA Technologies, Inc. is a pharmaceutical company focused on health security, primarily developing treatments for smallpox. As of March 2025, it reported net sales of $7 million and has a market cap of $450.08 million.

Overview: <BR>SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market, specializing in treatments for smallpox.<BR><BR>Financial Snapshot: <BR>Net Sales: 7 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 450.08 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.75 <BR>Return on Equity: 22.45% <BR>Price to Book: 2.08 <BR><BR>Contact Details: <BR>Address: 31 E 62nd St, NEW YORK NY: 10065-8014 <BR>Tel: 1 212 6729100 <BR>Fax: 1 212 6973130 <BR>Website: https://www.siga.com/

Should I buy, sell or hold SIGA Technologies, Inc.?

Who are in the management team of SIGA Technologies, Inc.?

As of March 2022, the management team of SIGA Technologies, Inc. includes Dr. Eric Rose (Chairman), Dr. Phillip Gomez (CEO), and several independent directors: Mr. Julian Nemirovsky, Mr. James Antal, Mr. Thomas Constance, Ms. Julie Kane, and Mr. Joseph Marshall. They oversee the company's operations and strategic direction.

As of March 2022, the management team of SIGA Technologies, Inc. includes the following individuals:<BR><BR>- Dr. Eric Rose, Chairman of the Board<BR>- Dr. Phillip Gomez, Chief Executive Officer and Director<BR>- Mr. Julian Nemirovsky, Director<BR>- Mr. James Antal, Independent Director<BR>- Mr. Thomas Constance, Independent Director<BR>- Ms. Julie Kane, Independent Director<BR>- Mr. Joseph Marshall, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is SIGA Technologies, Inc. overvalued or undervalued?

As of June 30, 2025, SIGA Technologies, Inc. is considered an attractive investment due to its low P/E ratio of 9, favorable EV to EBITDA of 4.72, strong ROCE of 103.73%, and a year-to-date return of 47.59%, outperforming the S&P 500.

As of 30 June 2025, the valuation grade for SIGA Technologies, Inc. has moved from expensive to attractive, indicating a shift towards being undervalued. The company appears undervalued with a P/E ratio of 9, significantly lower than its peer Theravance Biopharma, Inc., which has a P/E of 48.04. Additionally, SIGA's EV to EBITDA ratio stands at 4.72, while its peer comparison shows a more favorable position against Theravance's negative EV to EBITDA. The company's strong ROCE of 103.73% further supports its attractiveness in the market.<BR><BR>In terms of returns, SIGA has shown a year-to-date return of 47.59%, outperforming the S&P 500's return of 12.22% during the same period, although it has lagged behind the index over the longer three and five-year periods. Overall, SIGA Technologies, Inc. is positioned as an attractive investment opportunity within the Pharmaceuticals & Biotechnology sector.

Is SIGA Technologies, Inc. technically bullish or bearish?

As of October 3, 2025, SIGA Technologies, Inc. has a mildly bullish trend, supported by bullish MACD and moving averages, despite mixed signals from other indicators and underperformance over the 3- and 5-year periods.

As of 3 October 2025, the technical trend for SIGA Technologies, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. Daily moving averages are bullish, but the KST shows a mixed signal with weekly bullish and monthly mildly bearish readings. The OBV is mildly bearish on a weekly basis, with no trend on a monthly basis. <BR><BR>In terms of performance, SIGA has outperformed the S&P 500 year-to-date with a return of 48.92% compared to 14.18%, and over the past year with 28.59% versus 17.82%. However, it has underperformed over the 3-year and 5-year periods. Overall, the current stance is mildly bullish, supported by the bullish MACD and moving averages, despite some mixed signals from other indicators.